Pfizer (PFE) closed at $29.74 in the latest trading session, marking a +1.11% move from the prior day. The stock outperformed the S&P 500, which registered a daily gain of 0.45%. Elsewhere, the Dow saw a downswing of 0.23%, while the tech-heavy Nasdaq appreciated by 0.84%.The drugmaker's stock has climbed by 3.37% in the past month, exceeding the Medical sector's gain of 3.16% and the S&P 500's gain of 2.54%.Analysts and investors alike will be keeping a close eye on the performance of Pfizer in its upcomin ...

no_limit_pictures Intro & Thesis I reinitiated my coverage of Pfizer Inc. (NYSE:PFE) stock at the end of December 2023 with a "Buy" rating, when the stock was trading at $27.86 apiece. Since then, I have published 3 more articles, which, ultimately, have proven effective in terms of relative and absolute performance: PFE's total return outpaced the S&P 500 index (SP500) (SPX) quite meaningfully. The index has remained stagnant, hovering around 0% over the past 3 months, while PFE gave a total return of over ...

Investment Thesis - Pfizer's stock delivered a total return of 6.5% since February, underperforming the broader market's 7.3% return [1] - The company secured FDA approval for its KP.2-adapted COVID-19 vaccine, positioning it well for the 2024-2025 season [1] - Core products like Eliquis, Vyndaqel, and newer oncology therapies, along with Seagen acquisitions, are driving growth [1] - Pfizer is expanding into obesity treatments and oncology through key R&D investments, diversifying its pipeline [1] - Technical indicators suggest potential stock strength, with RSI trending upward and early signs of accumulation in VPT [1][3] Technical Analysis - Pfizer's current stock price of $28.5 aligns with the pessimistic 2024 price target based on the 0.382 Fibonacci level [2] - The average price target of $31 (1.0 Fibonacci level) suggests modest upside, while the optimistic target of $33 (1.618 Fibonacci level) indicates potential for stronger gains [2][3] - RSI at 51.84 indicates neutral market sentiment, but the upward trend suggests potential stock strength [3] - VPT shows signs of upward reversal, indicating possible accumulation [3] - Historical seasonality data suggests stronger performance in October (62% chance of positive returns) and November (70% chance) [4] COVID-19 Vaccine Market - Pfizer's KP.2-adapted COVID-19 vaccine, developed with BioNTech, is FDA-approved for the 2024-2025 season [5][6] - The COVID-19 vaccine market is projected to reach $25.6 billion by 2024, with the US contributing $4.39 billion [7] - Pfizer expects the KP.2 vaccine to capture substantial market share, supported by FDA recommendations [6] - The market faces a compound annual growth rate of -17.64% from 2024 to 2029 [7] Financial Performance - Pfizer's Q2 2024 revenue reached $13.3 billion, marking 3% annual operational growth [8] - Excluding COVID-related products, operational revenue growth was 14% [8] - Adjusted gross margin improved to 79% from 76% last year, driven by a favorable sales mix of non-COVID products [8] - Core products like Eliquis, Vyndaqel, and Xtandi drove revenue growth, with Eliquis capturing a growing share of the oral anticoagulant market [9] - Nurtec experienced a 44% annual increase in global operational revenue [9] Oncology and R&D - Pfizer's oncology segment, bolstered by the Seagen acquisition, is seeing growth with products like Padcev, Xtandi, Lorbrena, and Braftovi-Mektovi [9] - Full FDA approval for Tivdak and positive CHMP opinions for Braftovi-Mektovi and Padcev in Europe are critical milestones [9] - R&D expenses increased by 2% operationally in Q2 2024, with a focus on obesity treatments like danuglipron, an oral GLP-1 receptor agonist [9] - Positive results from the Phase 3 CROWN study of Lorbrena in ALK-positive metastatic non-small cell lung cancer showed 60% of patients living beyond five years without disease progression [9] Manufacturing and Cost Management - Pfizer's Manufacturing Optimization Program aims to deliver $1.5 billion in savings by 2027, with savings expected to start in 2025 [9] - The program focuses on improving operational efficiency and realigning the cost base to hit pre-pandemic operating margins [9] - Fiscal year-end revisions show 20 EPS upward revisions and 16 revenue upward revisions, with only 3 revenue downward revisions [10] Revenue Risks and Market Competition - Pfizer remains partially dependent on COVID-19 products, with Q2 2024 COVID-related sales forecast at $8.5 billion [11] - The COVID-19 vaccine market is increasingly competitive, with companies like Moderna and new entrants developing alternatives [11] - Evolving virus strains and competitor advancements create challenges for sustaining market share [12] - Revenue estimates for December 2024 are $60.99 billion, with annual growth of 4.27%, and a P/S ratio of 2.70 [12] - By December 2025, revenue may reach $63.11 billion, with a forward P/S ratio of 2.60 [12] Long-Term Growth Narrative - Despite near-term challenges from fluctuating COVID-19 demand and market competition, Pfizer's strong core portfolio and strategic pipeline investments present a solid growth narrative in the long term [14]

It's not hard to see how these well-seasoned businesses could deliver heaps of passive income to patient investors.There are a million and one ways to make a buck on Wall Street, but some methods are more reliable than others. If you're an investor looking for a way to beef up your passive income stream or you simply want big gains, buying dividend-paying stocks and holding them is a relatively easy way to make it happen.Dividend-payers have to manage their cash more carefully than non-dividend-payers, whic ...

JHVEPhoto Investing in stocks is not for the faint-hearted. Investing in biotech stocks is certainly not for everyone. There are a lot of external factors at play determining the profitability of a biotech company, and even the biggest players in this industry are not immune to regulatory and competitive threats. As a growth investor, though, it is imperative for me to be comfortable with the risks associated with biotech companies, which is why I have invested in a few interesting companies in this spa ...

JHVEPhoto My thesis After publishing a bullish thesis on Pfizer (NYSE:PFE) on June 5, the stock initially rallied, climbing to over $30 per share by the end of July. This surge seemed to validate the optimistic outlook. Pfizer's initial momentum, unfortunately, didn't last. The stock price dropped sharply following the Q2 earnings report release. This decline was particularly notable given the broader market context. While the overall stock market grew by 3% during this period, Pfizer's stock went again ...

The most recent trading session ended with Pfizer (PFE) standing at $28.39, reflecting a +0.32% shift from the previouse trading day's closing. This change outpaced the S&P 500's 0.16% loss on the day. Elsewhere, the Dow saw an upswing of 0.09%, while the tech-heavy Nasdaq depreciated by 0.3%.Heading into today, shares of the drugmaker had lost 3.48% over the past month, lagging the Medical sector's gain of 4.7% and the S&P 500's gain of 3.64% in that time.Investors will be eagerly watching for the performa ...

Pfizer Inc. (NYSE:PFE) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 8:30 AM ET Company Participants David Denton - Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn All right, great. We're going to get started here. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. Very pleased to be hosting Pfizer this morning, CFO, Dave Denton. I'm Terence Flynn from ...

Pfizer Inc. (NYSE:PFE) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 8:30 AM ET Company Participants David Denton - Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn All right, great. We're going to get started here. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. Very pleased to be hosting Pfizer this morning, CFO, Dave Denton. I'm Terence Flynn from ...

Market Overview - Market volatility presents opportunities for investors to capitalize on discounted investment prospects, particularly in high-quality growth stocks facing price declines [1] - Economic concerns, including a potential U.S. economic slowdown and the Bank of Japan's interest rate hike, contribute to market turbulence [1] Investment Strategies - "Buying the dip" is a key value investing strategy that involves acquiring assets during market downturns, relying on thorough fundamental analysis [2] - Diversification across various sectors is essential to mitigate risk and align investments with financial goals and risk tolerance [2] Pfizer Analysis - Pfizer's stock has declined approximately 20% from its 52-week high, primarily due to concerns over falling COVID-19 vaccine sales [3] - The company has a diversified portfolio, including leading oncology drugs and a strategic $43 billion acquisition of Seagen, expected to add eight new drugs by 2030 [4] - Pfizer's second-quarter 2024 revenue exceeded $13 billion, marking a 3% operational increase year-over-year, with a 14% surge in revenue excluding COVID-19 products [4] - Key products like Vyndaqel and Nurtec ODT/Vydura have shown exceptional performance, with revenues increasing by 71% and 44% year-over-year, respectively [4] - Pfizer holds approximately $7 billion in cash reserves and offers a 5.89% dividend yield, indicating strong fundamentals and potential long-term growth [5] PayPal Analysis - PayPal commands approximately 40% of the global online payment processing market, with a recent stock price increase of 16% over the past month [7] - Despite trading 77% below its all-time high, PayPal's Q2 2024 revenue reached $7.9 billion, an 8% year-over-year increase, with operating income at $1.3 billion, a 17% increase [8] - Total payment volume expanded by 11% to nearly $417 billion, reflecting continued user engagement and strong cash flow generation [8][9] - PayPal's financial health is robust, with over $18 billion in cash and investments, positioning it as a compelling rebound play in the technology sector [9] SoFi Technologies Analysis - SoFi aims to be a leading platform for millennials in financial services, with a digital-first approach and a suite of products [11] - The company achieved $2.24 billion in revenue over the past year, with projected annual earnings growth of over 50% [12] - Despite recent profitability, SoFi's financial performance remains volatile, having reported a substantial net loss of $320 million in fiscal year 2022 [12][13] Conclusion - Pfizer, PayPal, and SoFi are potentially undervalued companies with strong fundamentals and growth prospects, making them attractive investment opportunities in a volatile market [14]